Effect of topical heparin and levomenol on atopic dermatitis: a randomized four‐arm, placebo‐controlled, double‐blind clinical study

Arenberger, Petr; Drozenová, H.; Hladíková, Marie; Holcova, S.

doi:10.1111/j.1468-3083.2010.03950.x

Cited by 18 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on full‐text review, 12 reports failed to meet the inclusion criteria (see Fig. ), resulting in 26 studies that met the criteria for final analysis …”

Section: Resultsmentioning

confidence: 99%

Use of the hCONSORT criteria as a reporting standard for herbal interventions for common dermatoses: a systematic review

Ornelas

Routt

Kallis

et al. 2018

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Based on full‐text review, 12 reports failed to meet the inclusion criteria (see Fig. ), resulting in 26 studies that met the criteria for final analysis …”

Section: Resultsmentioning

confidence: 99%

Use of the hCONSORT criteria as a reporting standard for herbal interventions for common dermatoses: a systematic review

Ornelas

Routt

Kallis

et al. 2018

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Bisabolol alone can ameliorate itching and inflammation; however, combination of these two agents showed higher efficacy. 42 Shea butter is a fat derivation of Butyrospermum parkii kernels composed of five major fatty acids, including palmitic, stearic, oleic, linoleic, and arachidic acids. Stearic and oleic acids account for 85-90% of this fatty acids.…”

Section: Moisturizer For Atopic Dermatitismentioning

confidence: 99%

The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review

et al. 2017

View full text Add to dashboard Cite

Moisturizer is a major component of basic daily skin care, particularly in presence of epidermal barrier alteration and reduced epidermal water content. It is an important part of a dermatologist's strategy to maintain skin health as well as treating various dermatoses which co-exist with skin dryness and are linked to impaired skin barrier function, such as in atopic disorders as well as other types of dermatitis. Mastering the knowledge regarding mechanism of action, application, dosage, adverse effects as well as specific clinical usage of moisturizers is a must for a dermatologist in order to support their use, particularly for evidence-based, therapeutic purposes. This review discusses the use of moisturizer both for skin health maintenance as well as a definitive or adjuvant therapy for many kinds of dermatitis.

show abstract

“…There is reasonable evidence from this one trial 230,231 of benefit from combined heparin and levomenol treatment compared with vehicle and some evidence that the combination is significantly more effective than each of the treatments given separately. The subgroup analysis of children aged ≤ 12 years must be treated with caution as the numbers of participants were low and it is not clear whether this was a post hoc analysis or not.…”

Section: Overall Implications For Research and Practicementioning

confidence: 99%

“…This trial by Arenberger and colleagues, published separately in both German 230 and English, 231 compared a cream containing a combination of levomenol and heparin with a cream containing levomenol alone, a cream containing heparin alone and a cream without any active ingredient. Table 35 provides the risk-of-bias assessment for the new study.…”

Section: Studiesmentioning

confidence: 99%

Scoping systematic review of treatments for eczema

Nankervis

Kim

Delamere

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

BackgroundEczema is a very common chronic inflammatory skin condition.ObjectivesTo update the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) systematic review of treatments for atopic eczema, published in 2000, and to inform health-care professionals, commissioners and patients about key treatment developments and research gaps.Data sourcesElectronic databases including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Skin Group Specialised Register, Latin American and Caribbean Health Sciences Literature (LILACS), Allied and Complementary Medicine Database (AMED) and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from the end of 2000 to 31 August 2013. Retrieved articles were used to identify further randomised controlled trials (RCTs).Review methodsStudies were filtered according to inclusion criteria and agreed by consensus in cases of uncertainty. Abstracts were excluded and non-English-language papers were screened by international colleagues and data were extracted. Only RCTs of treatments for eczema were included, as other forms of evidence are associated with higher risks of bias. Inclusion criteria for studies included availability of data relevant to the therapeutic management of eczema; mention of randomisation; comparison of two or more treatments; and prospective data collection. Participants of all ages were included. Eczema diagnosis was determined by a clinician or according to published diagnostic criteria. The risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool. We used a standardised approach to summarising the data and the assessment of risk of bias and we made a clear distinction between what the studies found and our own interpretation of study findings.ResultsOf 7198 references screened, 287 new trials were identified spanning 92 treatments. Trial reporting was generally poor (randomisation method: 2% high, 36% low, 62% unclear risk of bias; allocation concealment: 3% high, 15% low, 82% unclear risk of bias; blinding of the intervention: 15% high, 28% low, 57% unclear risk of bias). Only 22 (8%) trials were considered to be at low risk of bias for all three criteria. There was reasonable evidence of benefit for the topical medications tacrolimus, pimecrolimus and various corticosteroids (with tacrolimus superior to pimecrolimus and corticosteroids) for both treatment and flare prevention; oral ciclosporin; oral azathioprine; narrow band ultraviolet B (UVB) light; Atopiclair™ and education. There was reasonable evidence to suggest no clinically useful benefit for twice-daily compared with once-daily topical corticosteroids; corticosteroids containing antibiotics for non-infected eczema; probiotics; evening primrose and borage oil; ion-exchange water softeners; protease inhibitor SRD441 (Serentis Ltd); furfuryl palmitate in emollient; cipamfylline cream; andMycobacterium vaccaevaccine. Additional research evidence is needed for emollients, bath additives, antibacterials, specialist clothing and complementary and alternative therapies. There was no RCT evidence for topical corticosteroid dilution, impregnated bandages, soap avoidance, bathing frequency or allergy testing.LimitationsThe large scope of the review coupled with the heterogeneity of outcomes precluded formal meta-analyses. Our conclusions are still limited by a profusion of small, poorly reported studies.ConclusionsAlthough the evidence base of RCTs has increased considerably since the last NIHR HTA systematic review, the field is still severely hampered by poor design and reporting problems including failure to register trials and declare primary outcomes, small sample size, short follow-up duration and poor reporting of risk of bias. Key areas for further research identified by the review include the optimum use of emollients, bathing frequency, wash products, allergy testing and antiseptic treatments. Perhaps the greatest benefit identified is the use of twice weekly anti-inflammatory treatment to maintain disease remission. More studies need to be conducted in a primary care setting where most people with eczema are seen in the UK. Future studies need to use the same core set of outcomes that capture patient symptoms, clinical signs, quality of life and the chronic nature of the disease.FundingThe National Institute for Health Research Programme Grants for Applied Research programme.

show abstract

Effect of topical heparin and levomenol on atopic dermatitis: a randomized four‐arm, placebo‐controlled, double‐blind clinical study

Abstract: The combination of levomenol and heparin proved to be significantly more efficacious in the treatment of pruritus and inflamed skin than the preparations of the single components.

Cited by 18 publications

References 14 publications

Use of the hCONSORT criteria as a reporting standard for herbal interventions for common dermatoses: a systematic review

Use of the hCONSORT criteria as a reporting standard for herbal interventions for common dermatoses: a systematic review

The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review

Scoping systematic review of treatments for eczema

Contact Info

Product

Resources

About